News for 'Alembic Pharmaceuticals'

Top Pharma Firms Maintain Volume Growth Amid Market Shift to Chronic Therapies

Top Pharma Firms Maintain Volume Growth Amid Market Shift to Chronic Therapies

Rediff.com22 Sep 2026

India's 10 largest pharmaceutical companies have consistently maintained positive average volume growth throughout 2026, while smaller rivals have experienced more erratic performance, driven by a market shift towards chronic and sub-chronic therapies.

8 Of India's Oldest Companies

8 Of India's Oldest Companies

Rediff.com11 Nov 2025

Which were India's first companies that still exist today? Many trace their origins to over a century back. These venerable organisations are business entities. But they chronicle the beginnings of Corporate India.

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Rediff.com30 Jun 2025

The Indian pharmaceutical industry is likely to benefit from a major wave of patent expiries in the US, as small-molecule drugs worth $63.7 billion are expected to go off-patent between 2025-29, a 65 per cent rise over the previous five years, according to a report by Antique stock broking limited.

Sons rise at Alembic

Sons rise at Alembic

Rediff.com3 Sep 2005

Alembic to acquire 'Yutopar' from Dutch firm

Alembic to acquire 'Yutopar' from Dutch firm

Rediff.com23 Jun 2003

Alembic Ltd would be acquiring brand and trademark rights for 'Yutopar' drug from Dutch pharma entity Solvay Pharmaceuticals BV for an undisclosed amount, subject to regulatory approvals.

Meet the man who will now run the IPL

Meet the man who will now run the IPL

Rediff.com26 Apr 2010

Newly-appointed Indian Premier League interim commissioner Chirayu Amin is no new face to Indian cricket administration. Besides being a vice-president of the Board of Control for Cricket in India and president of the Baroda Cricket Association, he is also a member of the Twenty20 extravaganza's governing council.

Alembic seeks allies in US to double sales

Alembic seeks allies in US to double sales

Rediff.com8 Sep 2008

The Rs 1,027-crore (Rs 10.27 billion) company has filed 13 abbreviated new drug applications and 22 drug master files with the US Food and Drug Administration and regulatory agencies in Europe for supply of formulations and active pharmaceutical ingredients. Some of the ANDAs challenge innovator patents and the company's strategy will be to partner with established companies in the US and Europe for marketing formulations, said Pranav Amin, director, Alembic.

5 more manufacturers to produce black fungus drug: Govt

5 more manufacturers to produce black fungus drug: Govt

Rediff.com21 May 2021

The Union health ministry on Friday said license has been given to five more manufacturers for production of Amphotericin-B, used in the treatment of black fungus, and they will start producing 1,11,000 vials of the drug per month from July.

20-30% new products may be open to USFDA inspection

20-30% new products may be open to USFDA inspection

Rediff.com23 May 2022

With all major US export-oriented drug manufacturing plants in the country up for inspection in 2022, some estimates peg that at least 20-30 per cent of the new product launches lined up for the US will be subject to on-site inspection by the US Food and Drug Administration (USFDA). The last two years saw limited physical inspections due to travel restrictions during the pandemic. "Pre-Covid, the frequency and number of inspections of manufacturing plants in India by USFDA had increased significantly," analysts from ICICI Securities Research noted. "With growing ANDA filings, especially for complex products. "We expect this trend to return with the environment normalising," analysts from ICICI Securities Research noted.

Prices of key Covid bulk drugs shoot up as demand rises

Prices of key Covid bulk drugs shoot up as demand rises

Rediff.com12 May 2021

The API of Paracetamol, a fever and pain medication, has grown 25 per cent from Rs 450-480 per kg in December 2020 to Rs 580-600 per kg in April. When compared to the pre-Covid prices of December 2019, the surge is much steeper -- around 140 per cent, reports Sohini Das.

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Rediff.com11 Jun 2024

The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. According to the latest data from US-based Centers for Medicare and Medicaid Services (CMMS), price erosion in calendar year 2024 (CY24) on a year-to-date (YTD) basis stood at a high of 15 per cent in the oral solid dosage (OSD) segment compared to a low of 1 per cent in CY23. This erosion, according to a report by Antique Stock Broking, was the highest in the last three years.

Mid-cap selloff: Don't press the panic button, say experts

Mid-cap selloff: Don't press the panic button, say experts

Rediff.com7 Jun 2017

Despite the recent fall, the Nifty Midcap 100 index has outperformed by gaining 20 per cent till date in this year calendar year.

Mid-cap selloff: Don't press the panic button, say experts

Mid-cap selloff: Don't press the panic button, say experts

Rediff.com7 Jun 2017

Despite the recent fall, the Nifty Midcap 100 index has outperformed by gaining 20 per cent till date in this year calendar year.

Drugs ban: Partial relief for Wockhardt, Glaxo & Griffon

Drugs ban: Partial relief for Wockhardt, Glaxo & Griffon

Rediff.com18 Mar 2016

The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.

Govt may now cap prices of antibiotics

Govt may now cap prices of antibiotics

Rediff.com7 Oct 2019

The intention of the government is to cap prices of drugs that are essential and which the public widely uses.

Nifty ends at 8-month closing high on F&O expiry

Nifty ends at 8-month closing high on F&O expiry

Rediff.com30 Jun 2016

Financial shares were among the top Sensex gainers along with auto and pharma shares.

Markets end flat; Wipro cracks 7%

Markets end flat; Wipro cracks 7%

Rediff.com21 Apr 2016

IT majors led the decline.

Note ban shadow lingers over one in four BSE 200 stocks

Note ban shadow lingers over one in four BSE 200 stocks

Rediff.com30 Mar 2017

Quite a few large- and mid-cap stocks are yet to recover from the note ban, pharma, banking and rural demand-based industries among laggards.

'Famotidine may become the next HCQ for Covid-19'

'Famotidine may become the next HCQ for Covid-19'

Rediff.com10 May 2020

Researchers at Northwell Health in New York are testing the effects on Famotidine (used in high intravenous doses) on Covid-19 patients as a potential treatment. After the hospital announced its clinical trials, it led to a drug shortage in the US. Back home, however, there has not been any surge in the demand for Famotidine yet.

India Inc on bonus share binge

India Inc on bonus share binge

Rediff.com23 Apr 2004

Pharma sector profits in June to rise

Pharma sector profits in June to rise

Rediff.com13 Jul 2010

The rupee's appreciation of 6.4 per cent against the dollar and 12 per cent against the euro is likely to hurt the first-quarter performance of the pharmaceutical sector, indicate a results' preview by broking houses.

TCS, Infosys in Forbes 'Super 50' list

TCS, Infosys in Forbes 'Super 50' list

Rediff.com26 Jul 2016

Companies which have been dropped from the list include Tata Motors, Hindustan Unilever, MRF, Glaxo SmithKline Consumer Healthcare, Pfizer, Dr Reddy's Labs, Glenmark Pharmaceuticals, HDFC and Kotak Mahindra Bank

New drug pricing order challenged in court

New drug pricing order challenged in court

Rediff.com1 Aug 2013

The move is expected to delay the introduction of low-priced medicines in the market.

Is my portfolio good?'

Is my portfolio good?'

Rediff.com31 Jan 2022

Ajit Mishra, vice president, research, Religare Broking, answers your queries.

US regulator tightens drug approval norms

US regulator tightens drug approval norms

Rediff.com29 Jul 2013

Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics

ASK AJIT: 'How can I make money?'

ASK AJIT: 'How can I make money?'

Rediff.com24 Feb 2021

Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.

ASK AJIT: 'Which shares to buy short term and long term?'

ASK AJIT: 'Which shares to buy short term and long term?'

Rediff.com17 Jan 2022

Ajit Mishra, vice president, research, Religare Broking, answers your stockmarket queries.

Drug regulator lets pharma firms fix own penalty

Drug regulator lets pharma firms fix own penalty

Rediff.com20 Jan 2014

Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.

ASK AJIT: How to get 20% return on shares?

ASK AJIT: How to get 20% return on shares?

Rediff.com17 Dec 2021

Ajit Mishra, vice president, research, Religare Broking, answers your queries.

Drugs of 7 Indian pharma firms in EMA's suspension list

Drugs of 7 Indian pharma firms in EMA's suspension list

Rediff.com4 Feb 2015

Indian pharma firms under European drug regulator's scanner.

ASK AJIT: Stocks To Buy, Hold, Sell

ASK AJIT: Stocks To Buy, Hold, Sell

Rediff.com11 Mar 2022

Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.

Why India's pharma cos prefer Gujarat over tax havens

Why India's pharma cos prefer Gujarat over tax havens

Rediff.com23 Sep 2017

Gujarat has around 3,000 licensees for allopathic drug manufacturing, apart from around seven homeopathic licensees, 500 ayuvedic and 600-700 cosmetics licensees

Indian drug cos to benefit as US expedites generic clearances

Indian drug cos to benefit as US expedites generic clearances

Rediff.com12 May 2014

Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.

First-time investor: 'I can afford only low-price stocks'

First-time investor: 'I can afford only low-price stocks'

Rediff.com12 Jan 2021

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

ASK AJIT: Stocks to hold or exit

ASK AJIT: Stocks to hold or exit

Rediff.com8 Dec 2020

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Best and worst performing stocks in 2015

Best and worst performing stocks in 2015

Rediff.com30 Nov 2015

Natco Pharma, Wockhardt and Marksans have rallied between 50 and 70 per cent in the year till date.